Azienda Ospedaliero Universitaria Pisana
Verified site
Pisa, Italy
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying treatments for patients with stage IV colorectal cancer who currently show no evidence of the disease. The study will explore the effects of two medications: durvalumab, also known by its code name MEDI4736, and regorafenib, which is referred to as BAY 734506. Durvalumab is given as a solution for infusion, meaning it is administered directly into the bloodstream through a vein, while regorafenib is taken orally as a film-coated tablet.
The purpose of this study is to evaluate how well these treatments work in preventing the return of cancer in patients who have already undergone treatment and currently have no detectable disease. Participants will be randomly assigned to receive either the combination of durvalumab and regorafenib or no additional treatment. The study will last for up to 12 months, during which time the health of the participants will be closely monitored.
The main goal is to determine if the combination of these medications can help patients remain free of cancer for a longer period. The study will also look at the overall survival of participants, any side effects they may experience, and how well they adhere to the treatment plan. This research aims to provide valuable insights into improving outcomes for patients with advanced colorectal cancer.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
5 criteria
1 criterion
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a type of medication known as an immunotherapy. It works by helping your immune system recognize and attack cancer cells. In this trial, durvalumab is used to try to prevent the return of colorectal cancer after it has been treated and there is no evidence of disease.
is a medication that targets specific proteins in cancer cells, which can help stop the cancer from growing and spreading. It is used in this trial to see if it can help keep colorectal cancer from coming back after treatment.
Durvalumab is administered as an intravenous infusion, meaning it is given directly into the bloodstream through a vein. It is currently being studied in clinical trials for its effectiveness in treating stage IV colorectal cancer patients who show no evidence of disease. The main therapeutic indication for durvalumab in this trial is to improve disease-free survival, which means helping patients stay free of cancer for longer periods. At the molecular level, durvalumab works by blocking a protein called PD-L1, which helps the immune system recognize and attack cancer cells. It is classified as an immunotherapy drug, specifically a checkpoint inhibitor, which helps the body's immune system fight cancer.
Regorafenib is taken orally in the form of a tablet, which means it is swallowed and absorbed through the digestive system. It is being tested in clinical trials for its potential to help stage IV colorectal cancer patients who have no evidence of disease. The main therapeutic goal of regorafenib in this context is to extend the time patients remain free of cancer. Regorafenib works by inhibiting multiple proteins involved in cancer cell growth and blood vessel formation, effectively slowing down or stopping the growth of cancer cells. It is classified as a multi-kinase inhibitor, a type of targeted therapy that interferes with specific pathways in cancer cells.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.